An obvious first way to address these problems is by taking advantage of ICBs, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, and others in development, which have been successful in a significant fraction of patients with melanoma or lung cancer. The gene discussed is CTLA4; the disease is lung carcinoma.